PROTEOMICS OF TEAR IN INACTIVE THYROID-ASSOCIATED OPHTHALMOPATHY

被引:0
|
作者
Jiang, L. [1 ]
Wei, R. [1 ]
Diao, J. [1 ]
Ding, H. [1 ]
Wang, W. [1 ]
Ao, R. [1 ]
机构
[1] Tongji Univ, Tongji Hosp, Sch Med, Dept Ophthalmol, Shanghai, Peoples R China
基金
中国国家自然科学基金;
关键词
Tear proteomics; Thyroid-associated ophthalmopathy; Inactive stage; Bioinformatics; GRAVES OPHTHALMOPATHY; HORMONE; ORBITOPATHY; DISEASE;
D O I
暂无
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background. Thyroid-associated ophthalmopathy (TAO), one of the most common orbital diseases in adults, seriously reduces patients' quality of life. Although human tear proteomics identified many abnormal expressed proteins and proposed several pathogeneses of TAO, most of these studies focused on the active stage or mixed types in TAO. In this study we identified significantly changed proteins and preliminary revealed the potential signalling pathways and mechanisms of TAO with the late, inactive stage. Patients and Methods. Tears from TAO patients (n=6) with a CAS score < 3 and 6 control healthy subject were collected. The pooled tears were further fractionated using high pH reversed-phase chromatography, then submitted to LC-MS/MS and subsequent bioinformatic analysis. Results. Proteomic profiling identified 107 significantly changed proteins between the inactive stage of TAO patients and healthy cases. Among these proteins, 62 were upregulated, and 45 were downregulated in TAO cases compared to healthy individuals. Enrichment analysis revealed that the immune system, cell cycle, metabolism (carbohydrate metabolism and metabolism of cofactors and vitamins), protein synthesis and degradation might play a vital role in the progress of inactive TAO. The present investigation represents the first proteomic tear study of TAO patients in the inactive stage. Conclusion. The results shed light on the differences between inactive TAO patients and healthy cases, thus enabling us to understand better the molecular mechanisms and potential targets for the treatment of inactive TAO.
引用
收藏
页数:13
相关论文
共 50 条
  • [21] Thyroid-associated ophthalmopathy: a new sign
    Gallenga, PE
    Mastropasqua, L
    Mancini, A
    Ciancaglini, M
    Zuppardi, E
    Lobefalo, L
    ULTRASONOGRAPHY IN OPHTHALMOLOGY XV, 1997, 61 : 371 - 376
  • [22] Ophthalmological evaluation in thyroid-associated ophthalmopathy
    Åsman, P
    ACTA OPHTHALMOLOGICA SCANDINAVICA, 2003, 81 (05): : 437 - 448
  • [23] The Diagnosis and Treatment of Thyroid-Associated Ophthalmopathy
    Daniel J. Gould
    Forrest S. Roth
    Charles N. S. Soparkar
    Aesthetic Plastic Surgery, 2012, 36 : 638 - 648
  • [24] Teprotumumab Treatment for Thyroid-Associated Ophthalmopathy
    Smith, Terry J.
    EUROPEAN THYROID JOURNAL, 2020, 9 (SUPPL 1) : 31 - 39
  • [25] The Diagnosis and Treatment of Thyroid-Associated Ophthalmopathy
    Gould, Daniel J.
    Roth, Forrest S.
    Soparkar, Charles N. S.
    AESTHETIC PLASTIC SURGERY, 2012, 36 (03) : 638 - 648
  • [26] AZATHIOPRINE IN THE TREATMENT OF THYROID-ASSOCIATED OPHTHALMOPATHY
    PERROS, P
    WEIGHTMAN, DR
    CROMBIE, AL
    KENDALLTAYLOR, P
    ACTA ENDOCRINOLOGICA, 1990, 122 (01): : 8 - 12
  • [27] Animal models of thyroid-associated ophthalmopathy
    Ludgate, ME
    THYROID, 2002, 12 (03) : 205 - 208
  • [28] 2021 update on thyroid-associated ophthalmopathy
    Neag, E. J.
    Smith, T. J.
    JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION, 2022, 45 (02) : 235 - 259
  • [29] Medical treatment for thyroid-associated ophthalmopathy
    Perros, P
    Kendall-Taylor, P
    THYROID, 2002, 12 (03) : 241 - 244
  • [30] Current management of thyroid-associated ophthalmopathy
    Kendall-Taylor, P
    CLINICAL ENDOCRINOLOGY, 1998, 49 (01) : 11 - 12